1-7 of 7
Hong Wang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Systemic Checkpoint Blockade by PD-L1 Single-Chain Antibody Confers Potent Antitumor Immunity and Long-term Survival

Hong Wang, Vinayak Khattar, Jonathan A. Hensel, Reading Ashton, Yun Lu, Anna G. Sorace, Yong Wang, Jessy S. Deshane, Joshua L. Mieher, Champion Deivanayagam, Selvarangan Ponnazhagan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (11): 1710–1721.
https://doi.org/10.1158/1535-7163.MCT-22-0010
Published: 03 November 2022
View article titled, Systemic Checkpoint Blockade by PD-L1 Single-Chain Antibody Confers Potent Antitumor Immunity and Long-term Survival
Open the PDF for Systemic Checkpoint Blockade by PD-L1 Single-Chain Antibody Confers Potent Antitumor Immunity and Long-term Survival in another window
Includes: Supplementary data
Journal Articles

Abstract P164: Identification of the p53 negative feedback loop as a target for enhancing selinexor activity in neuroblastoma

Rosa Nguyen, Hong Wang, Ming Sun, Dong Geun Lee, Junmin Peng, Carol J. Thiele
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P164.
https://doi.org/10.1158/1535-7163.TARG-21-P164
Published: 01 December 2021
View article titled, Abstract P164: Identification of the p53 negative feedback loop as a target for enhancing selinexor activity in neuroblastoma
Journal Articles

Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma

Javier Martín-Broto, Antonio López Pousa, Andrew S. Brohl, Brian A. Van Tine, Benjamin Powers, Silvia Stacchiotti, Jean-Yves Blay, James S. Hu, Gerard J. Oakley, III, Hong Wang, Anna M. Szpurka, Donna E. Levy, Gary Mo, Matteo Ceccarelli, Robin L. Jones
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2021) 20 (1): 132–141.
https://doi.org/10.1158/1535-7163.MCT-20-0441
Published: 05 January 2021
View article titled, Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma
Open the PDF for Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma in another window
Includes: Supplementary data
Journal Articles

RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity

Hong Wang, Reading Ashton, Jonathan A. Hensel, Joo Hyoung Lee, Vinayak Khattar, Yong Wang, Jessy S. Deshane, Selvarangan Ponnazhagan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (12): 2585–2597.
https://doi.org/10.1158/1535-7163.MCT-20-0378
Published: 02 December 2020
View article titled, RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity
Open the PDF for RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity in another window
Includes: Supplementary data
Journal Articles

Abstract C197: Accurins improve the pharmacokinetics, pharmacodynamics, tolerability and anti-tumor activity of the AKT inhibitor MK-2206

Louise Cadzow, Michael H. Lam, Young Ho Song, Maria Figueiredo, Hong Wang, David De Witt, Vincenzo Pucci, Jan-Rung Mo, Eric Lewis-Clark, Heidi Ferguson, Marian Gindy, Susan Low, Steve Zale, Jeff Hrkach, Caroline McGregor, Brian J. Long
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C197.
https://doi.org/10.1158/1535-7163.TARG-15-C197
Published: 01 December 2015
View article titled, Abstract C197: Accurins improve the pharmacokinetics, pharmacodynamics, tolerability and anti-tumor activity of the AKT inhibitor MK-2206
Journal Articles

Abstract A38: In vitro and in vivo characterization of a novel NEK2 inhibitor MBM5 for the treatment of gastrointestinal cancer

Yanfen Fang, Xiongwen Zhang, Wenhao Hu, Yannan Kong, Hong Wang, Mengli Zhu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A38.
https://doi.org/10.1158/1535-7163.TARG-15-A38
Published: 01 December 2015
View article titled, Abstract A38: In vitro and in vivo characterization of a novel NEK2 inhibitor MBM5 for the treatment of gastrointestinal cancer
Journal Articles

UA62784, a novel inhibitor of centromere protein E kinesin-like protein

Meredith C. Henderson, Yeng-Jeng Y. Shaw, Hong Wang, Haiyong Han, Laurence H. Hurley, Gary Flynn, Robert T. Dorr, Daniel D. Von Hoff
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (1): 36–44.
https://doi.org/10.1158/1535-7163.MCT-08-0789
Published: 12 January 2009
View article titled, UA62784, a novel inhibitor of centromere protein E kinesin-like protein
Open the PDF for UA62784, a novel inhibitor of centromere protein E kinesin-like protein in another window
Includes: Supplementary data